Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.
Status:
Recruiting
Trial end date:
2023-09-25
Target enrollment:
Participant gender:
Summary
FIH, Phase 1, open-label, multi centre study of CB307, a trispecific Humabody® T-cell
enhancer, in patients with advanced and/or metastatic PSMA+ solid tumours to assess safety
and torelability to determine MTD and RP2D.